Spring Bank Pharmaceuticals, Inc.
113 Cedar Street
Ste S-7
Milford
Massachusetts
01757
United States
Tel: 508-473-5993
Website: http://www.springbankpharm.com/
Email: info@springbankpharm.com
75 articles about Spring Bank Pharmaceuticals, Inc.
-
CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
11/20/2020
Spring Bank Pharmaceuticals, Inc. announced that at its special meeting of stockholders held earlier , Spring Bank's stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Limited in connection with its proposed combination with F-star.
-
Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics1-for-4 Reverse Stock Split to be Effective November 20, 2020
11/19/2020
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier today, Spring Bank’s stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Limited (“F-star”)
-
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
11/6/2020
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock, payable
-
Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/2/2020
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.
-
Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results
8/10/2020
Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs
-
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
7/29/2020
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, and F-star Therapeutics, Limited (“F-star”), a privately-held clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies
-
Spring Bank Advances IV SB 11285 Clinical Program
6/3/2020
Clinical Poster for IV SB 11285 Phase 1a/1b trial presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
-
Spring Bank to Present at the Jefferies 2020 Virtual Global Healthcare Conference
5/26/2020
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, announced that it will be participating in the Jefferies Virtual Global Healthcare Conference, taking place June 2-4, 2020.
-
Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
5/20/2020
Spring Bank Pharmaceuticals, Inc. announced that a trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology Annual Meeting, which will be conducted virtually from May 29-June 2, 2020.
-
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
5/7/2020
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, announced its financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate and clinical development highlights.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
4/2/2020
Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient dosed in next cohort
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
-
Clinical Catch-Up: February 24-28
3/2/2020
The month of February ended with a flurry of clinical trial announcements. Here’s a look. -
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
2/14/2020
HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth quarter and year-ended December 31, 2019 and provided an update on recent corporate and clinical development highlights. “In January, we made the difficult decision to discontinue our development efforts
-
Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
1/29/2020
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has discontinued development of inarigivir soproxil, which was in Phase 2 development for the treatment of chronic hepatitis B virus (HBV).
-
The company based the decision on safety information after unexpected serious adverse events, including one patient death in its Phase IIb CATALYST trial.
-
Clinical Catch-Up: December 23-27
12/30/2019
With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look. -
Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program
12/26/2019
Spring Bank Pharmaceuticals, Inc. announced that the company has stopped dosing and enrolling patients in its Phase 2b CATALYST trials, which are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus.
-
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
12/9/2019
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus (HBV) poster presentations at HepDART 2019 being held December 8 - 12, 2019 in Kauai, Hawaii.